0

BRIDION از شرکت ORGANON SUB MERCK

اطلاعات داروی نمایش داده شده مستقیما از دیتابیس اطلاعات دارویی سازمان غذا و دارو آمریکا (FDA) استخراج می شود و مرتبا به روز رسانی می شود
داروی نمایش داده شده مورد تایید FDA می باشد و اطلاعات ثبت آن در زیر قابل مشاهده است

BRIDION از شرکت ORGANON SUB MERCK

New Drug Application (NDA): 022225

Company: ORGANON SUB MERCK

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
BRIDION SUGAMMADEX SODIUM EQ 500MG BASE/5ML (EQ 100MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

None

Yes Yes
BRIDION SUGAMMADEX SODIUM EQ 200MG BASE/2ML (EQ 100MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

None

Yes No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
12/15/2015 ORIG-1 Approval

Type 1 – New Molecular Entity

PRIORITY

Label (PDF)

Letter (PDF)

Review

Summary Review (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022225lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022225Orig1s000ltr.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000TOC.cfm
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000SumR.pdf

Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
01/22/2021 SUPPL-9 Labeling-Package Insert

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022225s007s009lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/022225Orig1s007, s009ltr.pdf

06/25/2021 SUPPL-8 Efficacy-Labeling Change With Clinical Data

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022225s008lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/022225Orig1s008ltr.pdf

01/22/2021 SUPPL-7 Efficacy-Labeling Change With Clinical Data

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022225s007s009lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/022225Orig1s007, s009ltr.pdf

06/09/2020 SUPPL-6 Efficacy-Labeling Change With Clinical Data

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022225s006lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/022225Orig1s006ltr.pdf

10/24/2016 SUPPL-1 Labeling-Package Insert

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022225s001lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/022225Orig1s001ltr.pdf

Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
06/25/2021 SUPPL-8

Efficacy-Labeling Change With Clinical Data

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022225s008lbl.pdf
01/22/2021 SUPPL-9

Labeling-Package Insert

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022225s007s009lbl.pdf
01/22/2021 SUPPL-7

Efficacy-Labeling Change With Clinical Data

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022225s007s009lbl.pdf
06/09/2020 SUPPL-6

Efficacy-Labeling Change With Clinical Data

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022225s006lbl.pdf
10/24/2016 SUPPL-1

Labeling-Package Insert

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022225s001lbl.pdf
12/15/2015 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022225lbl.pdf
حتما بخوانید : ACTIDIL از شرکت GLAXOSMITHKLINE
برچسب‌ها:

نظرات کاربران

خروج از نسخه موبایل